U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449325) titled 'Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)' on Feb. 26.
Brief Summary: VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Microvascular Angina
Intervention:
DEVICE: A-FLUX Reducer System
The VahatiCor ...